These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 37639781

  • 1. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W, Amin A, Ashton L, Herbert A.
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [Abstract] [Full Text] [Related]

  • 2. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H.
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 6. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K.
    Neurol Neurochir Pol; 2023 Jul; 57(4):371-378. PubMed ID: 37490356
    [Abstract] [Full Text] [Related]

  • 7. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L, Iut VC, Etchepare A, D'Eramo M, Grinspan A, Assefi A.
    Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
    [Abstract] [Full Text] [Related]

  • 8. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R, Al-Hashel J, Ahmed SF.
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [Abstract] [Full Text] [Related]

  • 9. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y, Wang Y, Wong SL, Yang D, Sundar M, Tundia N.
    Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B.
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P.
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [Abstract] [Full Text] [Related]

  • 13. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ.
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [Abstract] [Full Text] [Related]

  • 14. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    Adamec I, Brecl Jakob G, Rajda C, Drulović J, Radulović L, Bašić Kes V, Lazibat I, Rimac J, Cindrić I, Gržinčić T, Abičić A, Barun B, Gabelić T, Gomezelj S, Mesaroš Š, Pekmezović T, Klivényi P, Krbot Skorić M, Habek M.
    J Neuroimmunol; 2023 Sep 15; 382():578164. PubMed ID: 37536052
    [Abstract] [Full Text] [Related]

  • 15. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
    Aerts S, Khan H, Severijns D, Popescu V, Peeters LM, Van Wijmeersch B.
    Mult Scler Relat Disord; 2023 Jul 15; 75():104735. PubMed ID: 37192586
    [Abstract] [Full Text] [Related]

  • 16. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, Shaw C, Skibina O, Vucic S, Shuey N, Barnett MH, Parratt J, Butzkueven H, Jack D, Fabris J, Kalincik T.
    Mult Scler; 2021 Mar 15; 27(3):465-474. PubMed ID: 32530363
    [Abstract] [Full Text] [Related]

  • 17. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study).
    Arena S, Chisari CG, Toscano S, Bucello S, Grimaldi LM, Ragonese P, Realmuto S, Cottone S, Maimone D, Finocchiaro C, Reitano P, Patti F.
    Curr Neuropharmacol; 2024 Mar 15; 22(7):1271-1283. PubMed ID: 36946484
    [Abstract] [Full Text] [Related]

  • 18. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr 15; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 19. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K, Kaczyński Ł, Rolka M, Homa M, Staśkiewicz W, Paczwa P, Wójcik R, Kaczor MP, Rejdak K.
    Neurol Neurochir Pol; 2022 Apr 15; 56(6):480-489. PubMed ID: 36421066
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E.
    Mult Scler; 2023 May 15; 29(6):719-730. PubMed ID: 37012898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.